Polypodium Leucotomos

PreclinicalSmall molecule

HHenry Ford Health System

Polypodium Leucotomos is one of 2 small molecule programs targeting Polyp. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PolypCompleted

PolypPreclinical

Completed

Competition

Competitive Landscape

3 competitors in Polyp

#DrugCompanyPhaseTrials

Alanine

UUniversity Hospital, Gentofte, Copenhagen

Phase 1

1 2

Polypodium Leucotomos

HHenry Ford Health System

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Polyp1 trial

The Effects of Visible Light on the Skin After Administration of Oral Polypodium Leucotomos

Completed·HHenry Ford Health System·N/A·NCT02904798·22 enrolled

Photoaging1 trial

Efficacy of Polypodium Leucotomos Extract Decreasing UVA Premutagenic and Photoaging Markers

Completed·UUniversity of Miami·Phase 2·NCT00520910·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Polypodium Leucotomos. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Polypodium Leucotomos compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Polypodium Leucotomos. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Henry Ford Health System company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: HHenry Ford Health System

Polypodium Leucotomos

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Polyp1 trial

Photoaging1 trial

References

Drug Info

Quick Facts

Related News